Generex Biotechnology News

French drug maker Sanofi-Aventis SA says it has agreed to buy US health care company Chattem Inc.

Biotech drugmaker Generex on Monday reported positive results for a mid-stage study of its experimental cancer vaccine.

Generex Biotechnology Corporation today announced presentation of interim results from a Phase II efficacy study of a novel immunotherapeutic vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc.

STOCK MARKETING INC PRESENTS : Generex Biotechnology Corp., eDOORWAYS Corp., Wataire International, Inc., Lightwave Logic, Inc., EV Innovations, Inc., KAT Exploration Inc.

Generex Biotechnology Corporation , the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has signed a long-term agreement with Sanofi-Aventis Deutschland GmbH for the manufacture and supply of recombinant human insulin crystals for commercial and clinical trial use in Generex's ...

Generex Biotechnology Corp. said Wednesday it entered a supply agreement with Sanofi-Aventis that will give Generex the insulin it needs to test and market its diabetes drug candidate Generex Oral-lyn. Generex said a German subsidiary of Sanofi-Aventis will provide recombinant human insulin crystals for use in trials of the drug as well as sales ...

Drug stocks moved south early Wednesday, joining the broader market in negative territory.

The report also includes earnings and earnings per share, margin and return ratios, financial strength, growth ratios, dayA's sales outstanding, dayA's outstanding inventory, cash and short-term investments per share and total common shares outstanding.

Published in the journal Diabetes, Obesity and Metabolism, an independent review of clinical trials of Generex Oral-lyn shows that the oral insulin spray has a faster onset of action and shorter duration of action than insulin delivered subcutaneously.

According to GuruFocus Insider Data , the largest CFO buys during the past week were Information Services Group Inc , BioFuel Energy Corp.

As biotech companies and large pharma embark on paths to usher in more effective diabetes drugs to market, one of the more significant concerns regarding diabetes related drug development is safety.

Generex Biotechnology Corporation , the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has received confirmation from The NASDAQ Stock Market that the Company will be provided with an additional 180 calendar day period to regain compliance with the Capital Market's listing maintenance ...

Windstream Corporation - Sector: Technology Veeco Instruments Inc. - Sector: Technology Verigy Ltd.

Generex Biotechnology Corporation , the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that, in light of general market conditions, Generex will not exercise its right to issue and sell shares of its common stock under the At Market Issuance Sales Agreement that it entered into with Wm Smith & ...

InvestorSoup.com announces an investment report featuring Generex Biotechnologies Corp.

Generex Biotechnology Corporation , the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it will present clinical data at the 20th World Diabetes Congress of the International Diabetes Federation being held in Montreal, Canada, 18-22 October, 2009.

The United Kingdom's National Institute for Health and Clinical Excellence has recently begun the draft scope for the official Health Technology Appraisal of Generex's novel buccal insulin for the management of type 1 diabetes.

In response to a number of requests that I've received via email or comments asking for 'VFC's Take' on numerous stocks that readers have found, I'll do my best to address as many as I can, as long as everyone takes a few things into account while reading: - I have not thoroughly researched all of the stocks that I'm about to comment on.

Weekly Digest , a free investment research publication, announced the publication of a special report on investment opportunities in connection with the H1N1 "Swine Flu" Outbreak, including updated outlooks for Alpha Pro Tech , Novavax , Generex Biotechnology , Inovio Biomedical , AstraZeneca and several others.

Shares of Generex touched just above seventy six cents on above average volume on Monday morning after a New York Times article over the weekend highlighted the company's Ora-Lyn insulin spray product that uses the inside lining of the cheek to deliver insulin to the bloodstream.